Quest for the right Drug
קיורטן 10 מ"ג CURATANE 10 MG (ISOTRETINOIN)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
קפסולות ג'לטין רכות : CAPSULES SOFT GELATIN
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmacological properties : תכונות פרמקולוגיות
Pharmacodynamic Properties
5.1. Pharmacodynamic Properties Pharmacotherapeutic group: Retinoid for treatment of acne ATC code: D10B A01 Mechanism of action Isotretinoin is a stereoisomer of all-trans retinoic acid (tretinoin). The exact mechanism of action of isotretinoin has not yet been elucidated in detail, but it has been established that the improvement observed in the clinical picture of severe acne is associated with suppression of sebaceous gland activity and a histologically demonstrated reduction in the size of the sebaceous glands. Furthermore, a dermal anti-inflammatory effect of isotretinoin has been established. Clinical efficacy and safety Hypercornification of the epithelial lining of the pilosebaceous unit leads to shedding of corneocytes into the duct and blockage by keratin and excess sebum. This is followed by formation of a comedone and, eventually, inflammatory lesions. Isotretinoin inhibits proliferation of sebocytes and appears to act in acne by re-setting the orderly program of differentiation. Sebum is a major substrate for the growth of Propionibacterium acnes so that reduced sebum production inhibits bacterial colonization of the duct.
Pharmacokinetic Properties
5.2 Pharmacokinetic Properties Absorption The absorption of isotretinoin from the gastro-intestinal tract is variable and dose-linear over the therapeutic range. The absolute bioavailability of isotretinoin has not been determined, since the compound is not available as an intravenous preparation for human use, but extrapolation from dog studies would suggest a fairly low and variable systemic bioavailability. When isotretinoin is taken with food, the bioavailability is doubled relative to fasting conditions. Distribution Isotretinoin is extensively bound to plasma proteins, mainly albumin (99.9 %). The volume of distribution of isotretinoin in man has not been determined since isotretinoin is not available as an intravenous preparation for human use. In humans little information is available on the distribution of isotretinoin into tissue. Concentrations of isotretinoin in the epidermis are only half of those in serum. Plasma concentrations of isotretinoin are about 1.7 times those of whole blood due to poor penetration of isotretinoin into red blood cells. Biotransformation After oral administration of isotretinoin, three major metabolites have been identified in plasma: 4-oxo-isotretinoin, tretinoin, (all-trans retinoic acid), and 4-oxo-tretinoin. These metabolites have shown biological activity in several in vitro tests. 4-oxo-isotretinoin has been shown in a clinical study to be a significant contributor to the activity of isotretinoin (reduction in sebum excretion rate despite no effect on plasma levels of isotretinoin and tretinoin). Other minor metabolites include glucuronide conjugates. The major metabolite is 4-oxo-isotretinoin with plasma concentrations at steady state that are 2.5 times higher than those of the parent compound. Isotretinoin and tretinoin (all-trans retinoic acid) are reversibly metabolised (interconverted), and the metabolism of tretinoin is therefore linked with that of isotretinoin. It has been estimated that 20-30 % of an isotretinoin dose is metabolised by isomerisation. Enterohepatic circulation may play a significant role in the pharmacokinetics of isotretinoin in man. In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4-oxo-isotretinoin and tretinoin. No single isoform appears to have a predominant role. Isotretinoin and its metabolites do not significantly affect CYP activity. Elimination After oral administration of radiolabeled isotretinoin approximately equal fractions of the dose were recovered in urine and faeces. Following oral administration of isotretinoin, the terminal elimination half-life of unchanged drug in patients with acne has a mean value of 19 hours. The terminal elimination half-life of 4-oxo-isotretinoin is longer, with a mean value of 29 hours. Isotretinoin is a physiological retinoid and endogenous retinoid concentrations are reached within approximately two weeks following the end of isotretinoin therapy. Hepatic impairment Since isotretinoin is contraindicated in patients with hepatic impairment, limited information on the kinetics of isotretinoin is available in this patient population. Renal impairment Renal failure does not significantly reduce the plasma clearance of isotretinoin or 4-oxo- isotretinoin.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לצרכן
04.02.19 - עלון לצרכן 04.02.19 - עלון לצרכן 16.01.19 - עלון לצרכן אנגלית 16.01.19 - עלון לצרכן 04.02.19 - עלון לצרכן אנגלית 16.01.19 - עלון לצרכן עברית 04.02.19 - עלון לצרכן עברית 04.02.19 - עלון לצרכן ערבית 16.11.20 - עלון לצרכן 16.11.20 - עלון לצרכן 16.11.20 - עלון לצרכן 27.03.18 - עלון לצרכן אנגלית 11.01.23 - עלון לצרכן אנגלית 11.01.23 - עלון לצרכן עברית 11.01.23 - עלון לצרכן ערבית 21.09.23 - עלון לצרכן אנגלית 21.09.23 - עלון לצרכן עברית 21.09.23 - עלון לצרכן ערבית 01.01.24 - עלון לצרכן עברית 25.01.24 - עלון לצרכן אנגלית 25.01.24 - עלון לצרכן עברית 25.01.24 - עלון לצרכן ערבית 21.07.24 - עלון לצרכן אנגלית 21.07.24 - עלון לצרכן עברית 21.07.24 - עלון לצרכן ערבית 21.07.24 - עלון לצרכן אנגלית 21.07.24 - עלון לצרכן 04.06.13 - החמרה לעלון 25.05.20 - החמרה לעלון 29.06.20 - החמרה לעלון 11.01.23 - החמרה לעלון 02.01.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
קיורטן 10 מ"ג